Life Sciences Blog

Health Canada Now Requiring Second-Language at Post-Authorization Phase

Mar 20, 2023 | Drug & Biologic Product Submissions, Drug Label Research, Life Sciences

 

Effective March 10, 2023, Health Canada changed submission requirements for second-language product monographs for human drugs. This change no longer requires the second language product monograph at the time of submission filing or review. However, both English and French languages need to be on the Drug Product Database (DPD) online and Drug and Health Product Portal (DHPP).

What is included? Rx and over-the-counter pharmaceutical drugs, biologics and radiopharmaceuticals.

What is not included? Labels and package inserts.

It is also important to note that both English and French product monographs are required post-authorization without exception. While this updated requirement provides a cushion of time before the second language product monograph is required, it does not change the product monographs ultimately.

Health Canada has provided this chart for easy reference:

Product monograph (PM) available on DPD Online At time of filing During review Post-authorization
None Both official languages preferred

Minimum is first language PM

Second language PM (if not already provided) Final second language PM
One official language PM only Both official language PMs preferred

Minimum is first language PM

Second language PM (if not already provided) Final second language PM
Both official language PMs First language PM only N/A Final second language PM

 

Health Canada is in the process of implementing regulations requiring labeling and listing to be submitted in XML PM (eXtensible Markup Language Product Monograph) format. Health Canada is currently accepting voluntary XML PM submissions and are “working hard to prepare the XML PM Guidance along with samples for public comment.”

We will provide more information about how these guidances will affect one another once it is available.

Questions about Health Canada XML PM or ready to get started with your submissions? Contact us at [email protected].

Source: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/changes-filing-requirements-product-monographs.html

About LexisNexis Legal & Professional

LexisNexis Legal & Professional® provides legal, regulatory, and business information and analytics that help customers increase their productivity, improve decision-making, achieve better outcomes, and advance the rule of law around the world. As a digital pioneer, the company was the first to bring legal and business information online with its Lexis® and Nexis® services. LexisNexis Legal & Professional, which serves customers in more than 150 countries with 11,300 employees worldwide, is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers.

About LexisNexis Reed Tech

LexisNexis Reed Tech brings clarity to innovation for businesses worldwide. We enable innovators to accomplish more by helping them make informed decisions, be more productive, comply with regulations, and ultimately achieve a competitive advantage for their business. Our Reed Tech suite of SingleSource™ for Medical Devices, SingleSource™ for Drug Products, and Navigator™ for Drug Labels enables life sciences companies to create product data management strategies and meet compliance deadlines on time. We are proud to directly support and serve these innovators in their endeavors to better humankind.

For more information, please visit ReedTech.com